BioSpace News Archive

Nautilus Biotechnology, a company pioneering a high-throughput, low-cost platform for quantifying the human proteome, today announced the appointment of Nick Nelson as Chief Business Officer. Joining the company on the heels of Nauti

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) (“Titan” or the “Company”) today announced a strategic restructuring designed to position it for future growth. Specifically, the Company plans to:

- More than three in four people with heart failure have difficulties with routine activities and heart failure is a leading cause of hospitalization in the U.S. - The study will evaluate the impact of digital health technologies on patient outcomes, clinical efficiencies and quality of life

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated interim results from a Phase 1/2a study of its lead product candidate, OpRegen ® , a retinal pigment epitheli

ValueSetters, Inc. (OTC:VSTR) announced that the company will partner with Vymedic to advance its innovative, patented approach to helping millions impacted by influenza, the common cold and other viruses. As an indication of its high conviction in the company, ValueSetters has taken an equity ownersh

OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in children and adults, today announced that they have initiated their sponsorship of the FDA Investigational New Drug (IND) application for OST-HER2 a

Global health service company Cigna Corporation will release its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a conference call on the same day.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced it has partnered with EVERSANA™, a leading provider of commercial services to the life science industry, to

-- The free, one-hour webinar will evaluate electrical power trends and issues at pharmaceutical facilities -- Participants will hear insights into infrastructure design, sustainability, and digitization -- Attendees earn professional education credits

Aegis Life is launched to pursue US-based development and commercialization of SARS-CoV-2 vaccine using the Entos Fusogenix technology and to support manufacturing and distribution of millions of DNA vaccine doses globally Aegis Life signs a license agreement with Nature Technology Corporation (NTC) to utilize Nanoplasmid™ technology in Aegis DNA vaccines EDMONTON, Alberta--( BUSINESS WIRE )-- Entos Pharmaceuticals (Entos), a Canadian biotechn